Aspire BioPharma, Inc. Price & Performance (ASBP)

Aspire Biopharma Holdings has successfully merged with PowerUp Acquisition Corp., officially becoming a Nasdaq-listed company. Trading under the ticker ASBP since February 20, 2025, the merger raised $3.8 million. The company plans to utilize the funds for advancing its innovative sublingual aspirin and other drug delivery products, targeting faster market entry.123

Aspire Biopharma is advancing its sublingual aspirin product, designed for emergencies like cardiac incidents. The high-dose formulation, offering rapid absorption, is set to enter Phase 1 trials in April 2025. The company’s patented technology bypasses the gastrointestinal tract, aiming for faster onset and fewer side effects, potentially transforming emergency care.456

Aspire Biopharma is preparing for key clinical milestones in 2025, including FDA meetings and trials for both high-dose and low-dose sublingual aspirin products. The company anticipates fast-track approval for its high-dose aspirin, with potential market launch by late 2025, signaling progress in its innovative drug delivery pipeline.476